WO2000044391A3 - Plasminogen kringle 4 region fragments and methods of use - Google Patents

Plasminogen kringle 4 region fragments and methods of use Download PDF

Info

Publication number
WO2000044391A3
WO2000044391A3 PCT/US2000/002091 US0002091W WO0044391A3 WO 2000044391 A3 WO2000044391 A3 WO 2000044391A3 US 0002091 W US0002091 W US 0002091W WO 0044391 A3 WO0044391 A3 WO 0044391A3
Authority
WO
WIPO (PCT)
Prior art keywords
kringle
fragments
endothelial cell
methods
proliferation inhibitor
Prior art date
Application number
PCT/US2000/002091
Other languages
French (fr)
Other versions
WO2000044391A2 (en
Inventor
Yuen W Shing
Michael S O'reilly
M Judah Folkman
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Priority to EP00908395A priority Critical patent/EP1147202A2/en
Priority to JP2000595693A priority patent/JP2002535372A/en
Priority to CA002360690A priority patent/CA2360690A1/en
Priority to AU29743/00A priority patent/AU2974300A/en
Publication of WO2000044391A2 publication Critical patent/WO2000044391A2/en
Publication of WO2000044391A3 publication Critical patent/WO2000044391A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Fragments of an endothelial cell proliferation inhibitor and method of use therefor are provided. The endothelial proliferation inhibitor is a protein derived from plasminogen, or more specifically is an angiostatin kringle 4 region fragment. The kringle 4 region fragments generally correspond to kringle 4 structures occurring within the endothelial cell proliferation inhibitor. The endothelial cell inhibiting activity of these fragments provides a means for inhibiting angiogenesis of tumors and for treating angiogenic-mediated disease.
PCT/US2000/002091 1999-01-28 2000-01-26 Plasminogen kringle 4 region fragments and methods of use WO2000044391A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00908395A EP1147202A2 (en) 1999-01-28 2000-01-26 Plasminogen kringle 4 region fragments and methods of use
JP2000595693A JP2002535372A (en) 1999-01-28 2000-01-26 Plasminogen kringle 4 region fragment and methods of use
CA002360690A CA2360690A1 (en) 1999-01-28 2000-01-26 Plasminogen kringle 4 region fragments and methods of use
AU29743/00A AU2974300A (en) 1999-01-28 2000-01-26 Plasminogen kringle 4 region fragments and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11761799P 1999-01-28 1999-01-28
US60/117,617 1999-01-28
US37071999A 1999-08-09 1999-08-09
US09/370,719 1999-08-09

Publications (2)

Publication Number Publication Date
WO2000044391A2 WO2000044391A2 (en) 2000-08-03
WO2000044391A3 true WO2000044391A3 (en) 2000-12-21

Family

ID=26815458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002091 WO2000044391A2 (en) 1999-01-28 2000-01-26 Plasminogen kringle 4 region fragments and methods of use

Country Status (5)

Country Link
EP (1) EP1147202A2 (en)
JP (1) JP2002535372A (en)
AU (1) AU2974300A (en)
CA (1) CA2360690A1 (en)
WO (1) WO2000044391A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517007A (en) * 1999-12-15 2003-05-20 エントレメッド インコーポレイテッド Endothelial cell growth inhibiting compositions and methods
US20020159992A1 (en) * 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
CN106890324A (en) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 A kind of method for preventing and treating diabetic nephropathy
JP6682008B2 (en) 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ Methods for preventing and treating diabetic nephropathy
WO2018107708A1 (en) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 Method for promoting expression of insulin receptor substrate-2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029242A1 (en) * 1994-04-26 1995-11-02 The Children's Medical Center Corporation Angiostatin and method of use for inhibition of angiogenesis
WO1996035774A2 (en) * 1995-04-26 1996-11-14 The Children's Medical Center Corporation Angiostatin fragments and aggregate angiostatin and methods of use
WO1998054217A1 (en) * 1997-05-30 1998-12-03 The Children's Medical Center Corporation Angiostatin fragments and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029242A1 (en) * 1994-04-26 1995-11-02 The Children's Medical Center Corporation Angiostatin and method of use for inhibition of angiogenesis
WO1996035774A2 (en) * 1995-04-26 1996-11-14 The Children's Medical Center Corporation Angiostatin fragments and aggregate angiostatin and methods of use
WO1998054217A1 (en) * 1997-05-30 1998-12-03 The Children's Medical Center Corporation Angiostatin fragments and method of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAO ET AL: "KRINGLE DOMAINS OF HUMAN ANGIOSTATIN. CHARACTERIZATION OF THE ANTI-PROLIFERATIVE ACTIVITY ON ENDOTHELIAL CELLS", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 46, 15 November 1996 (1996-11-15), pages 29461 - 29467, XP002086445, ISSN: 0021-9258 *
JI W R ET AL: "Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis.", FASEB JOURNAL, (1998 DEC) 12 (15) 1731-8., XP002141964 *
MENHART N ET AL: "FUNCTIONAL INDEPENDENCE OF THE KRINGLE 4 AND KRINGLE 5 REGIONS OF HUMAN PLASMINOGEN", BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 32, 1 January 1993 (1993-01-01), pages 8799 - 8806, XP002044611, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
EP1147202A2 (en) 2001-10-24
WO2000044391A2 (en) 2000-08-03
JP2002535372A (en) 2002-10-22
AU2974300A (en) 2000-08-18
CA2360690A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
CA2291892A1 (en) Angiostatin fragments and method of use
WO1996035774A3 (en) Angiostatin fragments and aggregate angiostatin and methods of use
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
WO2004009776A3 (en) TREATMENT OF TNFα RELATED DISORDERS
WO2001030381A3 (en) Use of csf-1 inhibitors
MX9804009A (en) Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor.
MX9702204A (en) RIBOZYME TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF PLASMA LIPOPROTEIN (a) [Lp(a)] BY INHIBITING APOLIPOPROTEIN (a) [APO(a)].
WO2002069900A3 (en) Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
WO2002026782A3 (en) Antiangiogenic polypeptides and methods for inhibiting angiogenesis
EP1067940A4 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO2003102016A3 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
WO2000001813A3 (en) Peptide inhibitors of androgen-independent activation of androgen receptor
WO2000044391A3 (en) Plasminogen kringle 4 region fragments and methods of use
WO2003026580A3 (en) Interactive therapeutic enclosures
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
WO1999058691A3 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
WO2001024684A3 (en) Methods for treatment of solid tumors and metastasis by gene therapy
DE60044350D1 (en) PROSTATE SPECIFIC GEN PCGEM1 AND METHODS OF USE FOR THE RECOGNITION, TREATMENT AND PREVENTION OF PROSTATE CANCER
WO2004026120A3 (en) Methods for diagnosing and treating tumors and suppressing cd promoters
WO1999057133A3 (en) Inhibitors of nf-kb activation
AU6291799A (en) Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
NO20016380L (en) Procedure for preventing tumor growth
AU2990300A (en) Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
WO2001023522A8 (en) Compositions and methods for p53-mediated repression of gene expression
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2360690

Country of ref document: CA

Ref country code: CA

Ref document number: 2360690

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000908395

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 595693

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000908395

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000908395

Country of ref document: EP